Open Veils
AboutBrowse

Open Veils · Answer

Marijuana and pain

The endocannabinoid system is a legitimate pain-modulation pathway suppressed in pharmacological research for decades. THC-dominant preparations show measurable, if modest, neuropathic pain relief in controlled trials, while the pharmaceutical synthetic analog nabilone outperforms dronabinol — a distinction the mainstream rarely publicizes. The real suppression story is not about efficacy but about why whole-plant research, entourage-effect formulations, and the work of researchers like Raphael Mechoulam were systematically defunded and schedule-blocked for generations.

Evidence

  • Raphael Mechoulam, the Israeli chemist who first isolated and synthesized THC in 1964 and later identified anandamide, laid the foundation for understanding endocannabinoid pain pathways — work that was largely ignored by Western pharmaceutical research until the 1990s.
  • Ethan Russo, former senior medical advisor at GW Pharmaceuticals and editor at the Journal of Cannabis and Cannabinoid Research, introduced the 'entourage effect' hypothesis: that whole-plant cannabinoid and terpene combinations produce synergistic analgesia that isolated compounds cannot replicate.
  • Joe Dispenza and researchers within the psychoneuroimmunology tradition, including Candace Pert's receptor mapping work, frame cannabinoid analgesia within a broader mind-body signaling model — the ECS as interface between emotional state and somatic pain perception.
  • His findings suggested the ECS is a homeostatic regulatory system, not merely a recreational drug target.
  • This line is almost never incorporated into clinical trial design.

Ask your own question

Share this answer